In oncology trials, regulators want to see more than just test results and survival metrics. While clinical indications such as tumor size, delayed disease progression, and absence of side effects are excellent measures of a treatment's impact, they don't describe the patient's experience with the treatment. That lack of perspective can impact whether a treatment is approved, covered and prescribed. Download this guide for 5 key recommendations on how to build an eCOA strategy in your next oncology trial that keeps your patient's voice front and center in their care.
Combine data science, technology, and analytics driven by artificial intelligence to support new efficiencies and business insights -- without additional capital investment.
Fast, flexible and proven, IQVIA’s industry-leading electronic clinical outcome assessment (eCOA) platform ramps up efficiencies, delivers real-time data, and sharpens insights through best-in-class technology and a better patient experience.
.svg){kind=icon}
